Abstract
The neuropeptide Y (NPY) is a neuropeptide with a role in the regulation of satiety and energy balance of
body weight, insulin release, cardiovascular and central endocrine systems. In order
to evaluate whether the NPY gene variations contribute to development of type 2 diabetes (T2DM), we have performed
a genetic association study for Leu7Pro (T1128 C) polymorphism of the NPY gene in impaired glucose tolerance (IGT) and T2DM. Genotyping experiments for this
non-synonymous single nucleotide polymorphism (SNP) in 263 patients with T2DM, 309
subjects with IGT and 469 non-diabetic healthy individuals in Swedish Caucasians were
performed by using Dynamic Allele Specific Hybridisation (DASH). We found that the
frequencies of the “risk” allele C in the subjects with IGT and the patients with
T2DM in Swedish men were 13 % (p = 0.002, OR = 3.70, 1.65 - 8.29 95 % CI) and 10 %
(p = 0.007, OR = 4.80, 1.47 - 11.33 95 % CI) respectively, which were significantly
higher than the C allele frequency in non-diabetic controls (6 %). Furthermore, we
found that the carriers with TC and CC genotypes in the subjects with IGT in Swedish
men had significantly higher fasting plasma glucose in comparison with the TT carriers
(5.6 ± 0.7 mmol/l vs. 5.2 ± 0.7 mmol/l, p = 0.021). The present study thus provides
the evidence that Leu7Pro polymorphism in the NPY gene is associated with IGT and T2DM in Swedish men, and indicates that the NPY gene variations contribute to development of T2DM. Questions of gender specificity
may be explained by genetic backgrounds, sense of coherence for stress and other factors
in environment.
Key words
Neuropeptide Y - type 2 diabetes - impaired glucose tolerance - single nucleotide
polymorphism - genetic association
References
- 1
Agardh E E, Ahlbom A, Andersson T, Efendic S, Grill V, Hallqvist J, Norman A, Ostenson C G.
Work stress and low sense of coherence is associated with type 2 diabetes in middle-aged
Swedish women.
Diabetes Care.
2003;
26
719-724
- 2
Bargsten G.
Cytological and immunocytochemical characterization of the insulin secreting insulinoma
cell line RINm5 F.
Arch Histol Cytol.
2004;
67
79-94
- 3
Billington C J, Briggs J E, Grace M, Levine A S.
Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism.
Am J Physiol.
1991;
260
R321-327
- 4
Billington C J, Briggs J E, Harker S, Grace M, Levine A S.
Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy
metabolism.
Am J Physiol.
1994;
266
R1765-1770
- 5
Blumenthal J B, Andersen R E, Mitchell B D, Seibert M J, Yang H, Herzog H, Beamer B A,
Franckowiak S C, Walston J D.
Novel neuropeptide Y1 and Y5 receptor gene variants: associations with serum triglyceride
and high-density lipoprotein cholesterol levels.
Clin Genet.
2002;
62
196-202
- 6
Cho Y R, Kim C W.
Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase
activation.
Biochem Biophys Res Commun.
2004;
314
773-780
- 7
Ding B, Bertilsson L, Wahlestedt C.
The single nucleotide polymorphism T1128 C in the signal peptide of neuropeptide Y
(NPY) was not identified in a Korean population.
J Clin Pharm Ther.
2002;
27
211-212
- 8
Ding B.
Distribution of the NPY 1128C allele frequency in different populations.
J Neural Transm.
2003;
110
1199-1204
- 9
Gu H F, Efendic S, Nordman S, Östensson C G, Brismar K, Brookes A J, Prince J P.
Quantitative trait loci near the insulin-degrading enzyme gene (IDE) contribute to
variation in plasma insulin levels.
Diabetes.
2004;
53
2137-2142
- 10
Howell M W, Jobs M, Gyllensten U, Brookes A J.
Dynamic allele-specific hybridisation: A new method for scoring single nucleotide
polymorphisms.
Nature Biotech.
1999;
17
87-88
- 11
Kallio J, Pesonen U, Kaipio K, Karvonen M K, Jaakkola U, Heinonen O J, Uusitupa M I,
Koulu M.
Altered intracellular processing and release of neuropeptide Y due to leucine 7 to
proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans.
FASEB J.
2001;
15
1242-1244
- 12
Karvonen M K, Pesonen U, Koulu M, Niskanen L, Laakso M, Rissanen A, Dekker J M, Hart L M,
Valve R, Uusitupa M I.
Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide
Y with high serum cholesterol and LDL cholesterol levels.
Nat Med.
1998;
4
1434-1437
- 13
Karvonen M K, Valkonen V P, Lakka T A, Salonen R, Koulu M, Pesonen U, Tuomainen T P,
Kauhanen J, Nyyssonen K, Lakka H M, Uusitupa M I, Salonen J T.
Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the
progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish
men.
Atherosclerosis.
2001;
159
145-151
- 14
Koehnke M D, Schick S, Lutz U, Willecke M, Koehnke A M, Kolb W, Gaertner I.
Severity of alcohol withdrawal symptoms and the T1128 C polymorphism of the neuropeptide
Y gene.
J Neural Transm.
2002;
109
1423-1429
- 15
Kuhl J, Hilding A, Östenson C-G, Grill V, Efendic S, Båvenholm P.
Characterization of subjects with early abnormalities of glucose tolerance in the
Stockholm Diabetes Prevention Program: The impact of gender and type 2 diabetes heredity.
Diabetologia.
2005;
48
35-40
- 16
Levine A S, Jewett D C, Cleary J P, Kotz C M, Billington C J.
Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure.
Peptides.
2004;
25
505-510
- 17
Makino K, Kataoka Y, Hirakawa Y, Ikeda A, Yamauchi A, Oishi A R.
A leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y was
not identified in the Japanese population.
J Clin Pharm Ther.
2001;
26
201-203
- 18
McCarthy J J, Meyer J, Moliterno D J, Newby L K, Rogers W J, Topol E J.
Evidence for substantial effect modification by gender in a large-scale genetic association
study of the metabolic syndrome among coronary heart disease patients.
Hum Genet.
2003;
114
87-98
- 19
Minth C D, Andrews P C, Dixon J E.
Characterization, sequence, and expression of the cloned human neuropeptide Y gene.
J Biol Chem.
1986;
261
11974-11979
- 20
Moltz J H, McDonald J K.
Neuropeptide Y: direct and indirect action on insulin secretion in the rat.
Peptides.
1985;
6
1155-1159
- 21
Morris M J, Pavia J M.
Increased endogenous noradrenaline and neuropeptide Y release from the hypothalamus
of streptozotocin diabetic rats.
Brain Res.
2004;
1006
100-106
- 22
Niskanen L, Karvonen M K, Valve R, Koulu M, Pesonen U, Mercuri M, Rauramaa R, Toyry J,
Laakso M, Uusitupa M I.
Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with
enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control
subjects.
J Clin Endocrinol Metab.
2000 a;
85
2266-2269
- 23
Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen M K, Valve R, Pesonen U,
Laakso M, Uusitupa M I, Koulu M.
Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with
retinopathy in type 2 diabetes.
Exp Clin Endocrinol Diabetes.
2000 b;
108
235-236
- 24
Pettersson-Fernholm K, Karvonen M K, Kallio J, Forsblom C M, Koulu M, Pesonen U, Fagerudd J A,
Groop P H. FinnDiane Study Group .
Leucine 7 to proline 7 polymorphism in the preproneuropeptide Y is associated with
proteinuria, coronary heart disease, and glycemic control in type 1 diabetic patients.
Diabetes Care.
2004;
27
503-509
- 25
Pihlajamaki J, Karhapaa P, Vauhkonen I, Kekalainen P, Kareinen A, Viitanen L, Pesonen U,
Kallio J, Uusitupa M, Laakso M.
The Leu7Pro polymorphism of the neuropeptide Y gene regulates free fatty acid metabolism.
Metabolism.
2003;
52
643-646
- 26
Takeuchi T, Gumucio D L, Yamada T, Meisler M H, Minth C D, Dixon J E, Eddy R E, Shows T B.
Genes encoding pancreatic polypeptide and neuropeptide Y are on human chromosomes
17 and 7.
J Clin Invest.
1986;
77
1038-1041
- 27
Tatemoto K, Carlquist M, Mutt V.
Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY
and pancreatic polypeptide.
Nature.
1982;
296
659-660
- 28
Tatemoto K.
Neuropeptide Y: complete amino acid sequence of the brain peptide.
Proc Natl Acad Sci USA.
1982;
79
5485-5489
- 29
Waldbieser G C, Minth C D, Chrisman C L, Dixon J E.
Tissue-specific expression of the human neuropeptide Y gene in transgenic mice.
Brain Res Mol Brain Res.
1992;
14
87-93
- 30
Zhu G, Pollak L, Mottagui-Tabar S, Wahlestedt C, Taubman J, Virkkunen M, Goldman D,
Heilig M.
NPY Leu7Pro and alcohol dependence in Finnish and Swedish populations.
Alcohol Clin Exp Res.
2003;
27
19-24
Harvest F. Gu
L6:B2, Diabetes Center Karolinska, Department of Molecular Medicine, Karolinska Hospital
Stockholm, 171 76
Sweden
Phone: + 46851779515
Fax: + 46 8 51 77 36 58
Email: harvest.gu@molmed.ki.se